With Telemedicine, Hospitals May Have More Flexible Access To 340B Drug Discounts
But should a patient with little connection to a 340B covered entity other than through a telehealth visit be considered eligible for a discounted drug under the program?
You may also be interested in...
PhRMA Starts New Year With Familiar Drug Pricing Proposals Targeting The Supply Chain
Hoping to revive interest in rebate reform, PhRMA releases study saying manufacturers retain a shrinking portion of gross branded drug revenues as products move through the supply chain. The pricing distortion underscores the importance of targeting practices by payers and hospitals, the trade group argues.
340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again
Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.
Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.